octreotide acetate

The addition of everolimus, a mammalian target of rapamycin inhibitor, to octreotide marginally improves the 6-month progression-free survival (PFS) rate...We present the first case of a refractory meningioma patient treated with combination PRRT and octreotide in a 66-year-old male who received 177Lu-DOTATATE 7.4 GBq (200 mCi) and intramuscular long-acting octreotide 40 mg every 8 weeks for four cycles followed by a single cycle of octreotide 40 mg monotherapy...A 7-week post-treatment MRI brain demonstrated stable disease with 11.5% reduction per RANO-Meningioma and a 2.6% reduction per RECIST 1.1 criteria. Combined PRRT and octreotide represents a promising therapeutic strategy for patients with refractory meningioma.

Preoperative management included long-acting octreotide, niacin, and guideline-directed heart failure therapy, followed by tumor resection...Primary ovarian neuroendocrine neoplasms can cause carcinoid syndrome and right-sided valvulopathy without liver metastasis, likely because ovarian venous drainage bypasses hepatic first-pass metabolism. Multidisciplinary care enables prompt diagnosis, preoperative stabilization, definitive resection, and coordinated surveillance.

The patient was treated with capecitabine and temozolomide (CAPTEM) chemotherapy, pembrolizumab, long-acting repeatable octreotide (octreotide LAR), and diazoxide for hypoglycemia management. This case highlights the expanding phenotypic spectrum of Lynch syndrome and suggests that P-NETs may represent a rare but clinically significant manifestation. Early recognition of this association supports comprehensive genetic testing, enables the use of precision immunotherapy, and underscores the need for expanded surveillance strategies in patients with atypical tumor profiles.

P3, N=154, Not yet recruiting, CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

P3, N=240, Recruiting, Novartis Pharmaceuticals | N=100 --> 240

The patient underwent cytoreductive debulking surgery, achieving approximately 70% tumor reduction, followed by long-acting octreotide therapy...This case report underscores the importance of early recognition and a multidisciplinary approach in managing indolent neuroendocrine tumors with multisite metastases. Combined surgical and medical strategies, including debulking surgery and octreotide therapy, can achieve durable disease control and favorable outcomes.

P2/3, N=256, Completed, Grupo Espanol de Tumores Neuroendocrinos | Active, not recruiting --> Completed

P3, N=240, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Sep 2030 --> Dec 2028

P4, N=62, Recruiting, Boston Children's Hospital | Not yet recruiting --> Recruiting | Phase classification: PN/A --> P4 | Not yet recruiting --> Recruiting

P3, N=427, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027

PRRT combined with everolimus-based immunosuppression has demonstrated controllable safety and preliminary antitumor activity in patients with relapsed NETLM after LT who have been strictly screened, but myelosuppression requires close monitoring and timely symptomatic treatment.

Initial long-acting octreotide treatment was ineffective in controlling hyperthyroidism and was discontinued after 5 months. Despite SSTR2/5 positivity, suboptimal response to octreotide suggests tumor heterogeneity or downstream signaling defects. Preoperative Lugol's solution should be considered when SSAs and methimazole fail.